/
LITS
$0.91+$0.01 (+1.27%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$30.6M
34M shares
52-week range
$0.69 – $3.23
9% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
12.57%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-2.26
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | $34.8M | $40.7M | $48.8M | $65.3M | $0 |
| Cost of revenue | $1.4M | $0 | $0 | $0 | $368.0K |
| Gross profit | $33.4M | $40.7M | $48.8M | $65.3M | −$368.0K |
| Gross margin | 96.0% | 100.0% | 100.0% | 100.0% | — |
| R&D | $69.4M | $85.6M | $52.5M | $16.6M | $3.9M |
| Operating income | −$60.4M | −$75.5M | −$36.8M | $14.5M | −$17.5M |
| EBITDA | −$41.0M | −$75.2M | −$36.4M | $25.8M | −$17.1M |
| Net income | −$41.3M | −$54.5M | −$31.8M | $17.8M | −$15.9M |
| Net margin | -118.7% | -133.8% | -65.2% | 27.2% | — |
| EPS (diluted) | -12.00 | -9.99 | -4.78 | 2.67 | -2.39 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $25M | $-3.71 | $-3.71–$-3.71 | 1 |
| 2027 | $25M | $-1.56 | $-1.56–$-1.56 | 1 |
| 2028 | $25M | $-1.56 | $-1.56–$-1.56 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.68
Price
$0.91
Implied upside
+194%
Peer comparison
Lite Strategy, Inc. Common Stock
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.
www.litestrategy.com- Employees
- 4
- IPO / List date
- Dec 18, 2003
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds LITS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,744,700 | $2.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LITS yet.
